Business
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif., March 25, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024.
About this update from An2 Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/aef7c61a2738e783071162a0d1b125a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wNZcUCn1KcBPecfLAoBtKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/aef7c61a2738e783071162a0d1b125a3","width":480,"height":270}},"lazy":false},{"type":"text","content":"Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC)","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 1 first in human study of AN2-502998, under development for Chagas disease, to start mid-2025 in healthy volunteers","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"Topline data for melioidosis observational trial expected in 2Q25; Phase 2 epetraborole study planned for 2H25","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"First oncology candidate(s) from boron chemistry platform on track to advance into development in 2H25","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"Cash, cash equivalents, and investments of $88.6 million at December 31, 2024 anticipated to fund operations through 2027 under current strategic plan","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., March 25, 2025--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024.","length":324,"tagName":"p"},{"type":"text","content":""Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on two patient-reported outcome measures in patients with treatment-refractory MAC lung disease. Building on these encouraging findings, we updated our statistical analysis plan to select QOL-B as the primary efficacy endpoint for the Phase 3 part of the study, for which we plan to unblind and announce topline results in the second quarter. Should the Phase 3 data support the findings from Phase 2, we plan to engage with th...